Pancreatic Cancer Research

Clinical trialPhase 2Not yet recruiting

Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.

Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized, Open-Label, Single-Center, Parallel-Group, Prospective Phase II Clinical Study.

NCT07854977↗ ClinicalTrials.gov, retrieved 5 November 2026

Outcome
Ongoing
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Start
November 2026
Expected end
May 2030
Enrollment
40 participants
Sites
1
Primary outcomes
Median Progression-Free Survival （mPFS）
Sponsor
Other
Results posted
No
Last update
2 October 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 10